Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context

The outcomes of Relapsed/Refractory (R/R) Diffuse Large B-cell lymphoma have been historically poor. The recent development of several novel therapies including CD19 directed agents has improved the prognosis of this disease significantly. Chimeric antigen receptor (CAR) T-cell therapy has drastical...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulhaq, Haifaa, Hwang, Andrew, Mahmood, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364833/
https://www.ncbi.nlm.nih.gov/pubmed/37492075
http://dx.doi.org/10.2147/OTT.S372783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364833/
https://www.ncbi.nlm.nih.gov/pubmed/37492075
http://dx.doi.org/10.2147/OTT.S372783

Ejemplares similares